Article Text

Download PDFPDF
Proton pump inhibitors and suppression of duodenal eosinophilia in functional dyspepsia
  1. Michael D E Potter1,2,
  2. Nicola K Wood2,3,
  3. Marjorie M Walker1,2,
  4. Michael P Jones2,4,
  5. Nicholas J Talley1,2
  1. 1 Faculty of Health and Medicine, University of Newcastle, Newcastle, New South Wales, Australia
  2. 2 Australian Gastrointestinal Research Alliance, University of Newcastle, Newcastle, New South Wales, Australia
  3. 3 Department of Anatomical Pathology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
  4. 4 Psychology Department, Macquarie University, Sydney, New South Wales, Australia
  1. Correspondence to Dr Michael D E Potter, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2305, Australia; michael.potter{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the study by Molina-Infante et al 1 regarding proton pump inhibitor (PPI) responsive oesophageal eosinophilia. The authors emphasise that the benefit of PPI therapy may be secondary to anti-inflammatory effects (blocking of STAT 6) rather than antisecretory properties, which raises the question whether PPI therapy may be beneficial in other eosinophilic disease of the gastrointestinal tract. We report here novel observations of the effect of PPI therapy on duodenal eosinophilia in patients with functional dyspepsia (FD) which lends further support to this hypothesis.

FD is characterised by bothersome postprandial symptoms that cannot be easily be explained at upper gastrointestinal endoscopy.2 It is further subdivided into the postprandial distress syndrome (PDS), comprising patients who report early satiety …

View Full Text


  • Contributors MDEP, NKW, MMW, MPJ, NJT: Preparation of the manuscript and figures. MMW, MPJ, NJT: Study design and rationale.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval Sydney West Area Health Service Human Research Ethics Committee.

  • Provenance and peer review Not commissioned; internally peer reviewed.